To assess the potential benefits of suppressing the hyperinflammatory state on disease outcomes, clinical trials have been registered and planned to evaluate the safety and therapeutic efficacy of using IL‐6 and IL‐1 blockers or Bruton's tyrosine kinase (a key signalling pathway in macrophage activation and cytokine production) small molecule inhibitor in severe COVID‐19 patients.9, 81, 125, 126, 127. This evidence concerns the gene IL1B and COVID-19.